ESR2 and breast carcinoma: At a concentration of 50 μM, it exerts anti-estrogenic effects in order to inhibit cell migration while, at a concentration of 5 μM, it exerts estrogenic effects by enhancing the invasion, migration, and development of lamellipodia on the ERα (−), ERβ (+) MDA-MB-231 breast cancer cell line.